* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4732 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Naturewise Biotech & Medicals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Naturewise Biotech & Medicals Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Naturewise Biotech & Medicals's Days Payable distribution charts can be found below:
* The bar in red indicates where Naturewise Biotech & Medicals's Days Payable falls into.
Naturewise Biotech & Medicals Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Naturewise Biotech & Medicals (ROCO:4732) has a Days Payable of 66.26 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Naturewise Biotech & Medicals and its competitors. This is 107% above median its historical median of 31.98. Over the past decade, Naturewise Biotech & Medicals' Days Payable has ranged from 12.78 to 66.68. According to the industry distribution chart, Naturewise Biotech & Medicals ranks #435 out of 699 companies in the Biotechnology industry, placing it in the top 62.2%.
Is Naturewise Biotech & Medicals' Days Payable too high?
Naturewise Biotech & Medicals' current Days Payable of 66.26 is 107% above median its 10-year median of 31.98. Over the past 10 years, this metric has ranged from a low of 12.78 to a high of 66.68. The Biotechnology industry median Days Payable is 112.84. Naturewise Biotech & Medicals' value of 66.26 is 41.3% below this industry median. Based on the distribution chart, Naturewise Biotech & Medicals ranks #435 out of 699 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Naturewise Biotech & Medicals has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Naturewise Biotech & Medicals' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Naturewise Biotech & Medicals ranks #435 out of 699 companies for Days Payable. This places Naturewise Biotech & Medicals in the lower half of its industry. The industry median Days Payable is 112.84. Naturewise Biotech & Medicals' value of 66.26 is 41.3% below this benchmark. Historically, Naturewise Biotech & Medicals' own Days Payable has ranged from 12.78 to 66.68 over the past decade. While the company's 10-year median is 31.98 vs. the industry median of 112.84, Naturewise Biotech & Medicals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 699 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Naturewise Biotech & Medicals's current Days Payable of 66.26 is 41.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Naturewise Biotech & Medicals and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Naturewise Biotech & Medicals's current Days Payable is 66.26, which is 107% above median its own 10-year median of 31.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Naturewise Biotech & Medicals stock overvalued right now?
Based on GuruFocus' analysis, Naturewise Biotech & Medicals (ROCO:4732) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$22.10, compared to a current price of NT$16.65 — trading 24.7% below its estimated fair value. The current Days Payable is 66.26, which is 107% above median its 10-year median of 31.98 and 41.3% below the Biotechnology industry median of 112.84. Naturewise Biotech & Medicals' overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Naturewise Biotech & Medicals (ROCO:4732), the current Days Payable is 66.26 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Naturewise Biotech & Medicals (ROCO:4732) Overvalued in 2026?
Based on GuruFocus' analysis, Naturewise Biotech & Medicals stock appears to be undervalued.
The current stock price of NT$16.65 is trading 24.7% below its estimated GF Value™ of NT$22.10.
GuruFocus considers Naturewise Biotech & Medicals to be Modestly Undervalued.
Key valuation signals for ROCO:4732:
Days Payable: 66.26 (107% above median its 10-year median of 31.98)
GF Value™: NT$22.10 vs. price of NT$16.65 (24.7% below fair value)
Industry Position: 41.3% below the Biotechnology median (#435 of 699)
No single metric tells the full story. See the ROCO:4732 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Naturewise Biotech & Medicals Business Description
Naturewise Biotech & Medicals Corp is a Taiwan-based drug development company that focuses on botanical drug and small molecule therapies. Its products include NBM-BMX Oral Softgel Capsule, Lipocol Forte Capsule, and PPLs Taiwan Green Propolis.
62GF Score
Get the complete analysis for ROCO:4732
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4732 has been successfully added to your 
